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ABSTRACT
The syndrome of resistance to thyroid hormone (RTH) is characterized by elevated serum 
free thyroid hormones (FT4 and FT3) in the presence of unsuppressed TSH levels, reflecting 
resistance to the normal negative feedback mechanisms in the hypothalamus and pituitary. 
The degree of resistance within peripheral tissues determines whether thyrotoxic clinical fea-
tures are associated with this condition. Classic features include attention deficit hyperactivity 
disorder, growth delay, tachycardia, and goiter. However, other features, such as frequent ear, 
nose and throat infections, hearing deficit, and decreased bone mass have recently been recog-
nized. The phenotype of RTH is variable, with most patients presenting with mild to moderate 
symptoms. In this report we describe a girl with familiar RTH and diabetes mellitus. This is, 
to our knowledge, the first report regarding this association. Nearly one year after long-term 
triiodothyroacetic acid (Triac) therapy, we observed a reduction of thyroid hormone levels 
with an amelioration of insulin resistance. The possible interactions between these disorders 
are discussed.
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Case report
IntroductIon
The syndrome of resistance to thyroid hormone 
(RTH; MIM 188570) is characterized by elevated 
serum free thyroid hormones (TH) in the presence 
of unsuppressed TSH levels, reflecting resistance 
to the normal negative feedback mechanisms in the 
hypothalamus and pituitary.1 The degree of resist-
ance within peripheral tissues determines whether 
thyrotoxic clinical features are associated with this 
condition.1
RTH is caused by a mutation in the TH receptor 
(TR)-ß gene (THRB; MIM 190160). To date, more 
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than 300 families with the RTH phenotype have been 
found to harbor mutations in this gene.2 The mutant 
TR interferes with the activity of normal TR to induce 
the clinical syndrome.3 Identification of an autosomal 
dominant mode of inheritance, in conjunction with 
the recognition that receptor mutants are functionally 
impaired, has led to the proposal that these abnormal 
proteins are able to inhibit the function of their wild-
type counterparts in a dominant negative manner.1 
However, sporadic de novo cases are also common, 
although recessive inheritance is rare.4 
The phenotype of RTH is variable, with most pa-
tients presenting with mild to moderate symptoms.5 
Since its first description by Refetoff et al in 1967,6 
classic features have been progressively identified, 
including attention deficit and hyperactivity disorder, 
growth delay, tachycardia, and goiter. However, other 
features, such as frequent ear, nose and throat infec-
tions, hearing deficit, and decreased bone mass, have 
recently been recognized.5 As RTH patients present 
with elevated TH levels and goiter, frequently accom-
panied by some manifestations of thyrotoxicosis, the 
condition is often misdiagnosed as Graves’ disease. 
However, exophthalmos has never been identified as 
a feature of RTH and thyroid auto-antibodies have 
been detected only in approximately 4% of patients.7 
In these patients, an impairment of the glucose 
metabolism has not, to our knowledge, been reported. 
In this case report, we describe a girl with THR and 
diabetes mellitus, while we also discuss the potential 
mechanisms of this association.
clInIcal report
The patient, a female aged 10 years and 7 months, 
was referred to our Paediatric Endocrinology Unit for 
low body mass index (BMI) and suspected diagnosis 
of hyperthyroidism.
The proposita was the third-born child of a non-
consanguineous marriage delivered normally at 40 
weeks after an uncomplicated pregnancy. Family 
history was suggestive of thyroid pathologies and type 
2 diabetes mellitus (T2DM); the mother showed a 
history positive for goiter, hyperthyroidism, and fasting 
hyperglycaemia, diagnosed until adolescence. Three 
aunts have a history of thyroid diseases with goiter and 
unspecified dysthyroidism. One of these also showed 
impaired glucose tolerance (IGT), starting from the 
age of 34 years. One brother died of sudden infant 
death syndrome at three months of age. The other 
brother, 18 yrs old, was without any medical problems.
At birth, the girl’s Apgar score was 10I-10V. Birth 
weight was 2.6 Kg (-1.90 SDS), length was 48 cm (-1.40 
SDS) and head circumference 33.5 cm (-1.03 SDS). 
The neonatal congenital hypothyroidism screening 
was negative.
At 10 years and 7 months of age the girl weighed 
26.6 kg (-1.75 SDS) and her height was 144 cm (-0.20 
SDS). BMI was 12.80 (-3.00 SDS), according Cac-
ciari et al.8 The girl had no dysmorphic features. Her 
pubertal staging was B2-PH1-AH1. Her history was 
positive for frequent headache episodes and learning 
difficulty in school. At physical examination she ap-
peared as hyperactive. There was no exophthalmos, 
muscle weakness or tremor. There was no erythema 
or onycholysis. The neurological and audiometric 
examinations were normal. Her blood pressure was 
110/70 mmHg and her pulse rate was 110 beats/min. 
The skeletal muscles appeared hypotrophic and the 
adipose tissue reduced. The patient’s thyroid gland 
was slightly and symmetrically enlarged.
Basal hormonal investigation revealed fT4 4.26 
ng/dL (normal range: 0.8-1.9), fT3 8.02 pg/mL (nor-
mal range: 1.6-4.8), TSH 3.90 μIU/mL (normal 
range: 0.4-4). Antibodies against thyroperoxidase, 
thyroglobulin, and TSHR were undetectable. The fun-
dus oculi, ECG, and echocardiography were normal. 
Ultrasound examination of the neck showed an 
in-place, slightly enlarged thyroid gland. Bone age, 
performed according to the Greulich and Pyle method, 
was correspondent to chronological age (10 years vs. 
10 years 7 months).
Other laboratory examinations showed normal 
haemoglobin levels (135 g/L; normal range: 120-150 
g/L), mean corpuscular volume (MCV) (75.7 fL; 
normal range: 75-90 fL), serum cortisol (18 mg/dL; 
08 AM normal range 5-25 mg/dL), adrenocortico-
tropic hormone (ACTH) (08 AM 35 pg/mL; normal 
range 9-52 pg/mL), 30’s prolactin (PRL) (100 mIU/L; 
normal range 63-426 mIU/L), total calcium (2.3 
mmol/L; normal range 2.2-2.7 mmol/L), phosphate 
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(1.12 mmol/L; normal range 1.09-1.4 mmol/L), 25-hy-
droxyvitamin D (30.5 ng/mL; normal value >30 ng/
mL), 1,25-dihydroxyvitamin D (65.5 pg/mL; normal 
range: 19.9-67 pg/mL); parathyroid hormone (PTH) 
(37.6 pg/mL; normal range: 12-72 pg/mL), bone al-
kaline phosphatase (82.3 U/L; normal range 40-140 
U/L), osteocalcin (90 ng/mL; normal range 45-110 
ng/mL), and urinary deoxypyridinoline (46 nM/mM 
creatinine; normal range 30-60 nM/mM creatinine) 
levels. Her blood chemistry was AST 23 IU/L, ALT 
36 IU/L, γ-GTP 27 IU/L, ferritin 10.5 ng/mL, HbA1c 
5.6%, triglycerides 138 mg/dL, total cholesterol 235 
mg/dL, HDL cholesterol 49 mg/dL, LDL cholesterol 
158 mg/dL, insulin 26 μU/mL, glycaemia 130 mg/dL. 
No excretion of glucose in the urine was detectable. 
However, an oral glucose tolerance test indicated 
diabetes mellitus with hyperinsulinism and insulin 
resistance: glycaemia was 131 mg/dL at 0’, and 205 
mg/dL at 120’, whereas insulin was 34.6 μU/mL at 
0’, and 78.8 μU/mL at 120’ (Table 1). Homeostasis 
Model Assessment - Insulin Resistance (HOMA-IR) 
index (11.19) and Matsuda index (1.29) indicated 
insulin resistance.
Coeliac disease screening was negative (IgA 129 
mg/dL; anti-tissue transglutaminase (tTG) antibod-
ies 0.5 U/mL). The HLA was DQ2 DR3, 11 DRB3* 
DRw52.
Routine cytogenetic investigations revealed an 
apparently normal female karyotype (46,XX). For 
the next diagnostic plan, the sequence analysis of 
the TRβ gene revealed a mutation in exon 9 and an 
amino acid alteration, namely, a substitution of valine 
for methonine at codon 313 (Met313Val) (Figure 
1). This mutation has not, to our knowledge, been 
Table 1. Thyroid hormone and TSH levels and metabolic evaluation before and after TRIAC administration
Before TRIAC (10 years 7 months) After TRIAC (11 years 9 months)
Height (SDS) -0.20 -0.11
Weight (SDS) -1.75 -1.83
BMI (SDS) -3.00 -2.78
FT4 (ng/dL) 4.26 2.47
FT3 (pg/mL) 8.02 5.23
TSH (μIU/mL) 3.90 2.60
Total cholesterol (mg/dL 235 176
HDL cholesterol (mg/dL) 49 53
LDL cholesterol (mg/dL) 158 101
Triglycerides (mg/dL) 138 108
OGTT
Glycaemia (mg/dl)
T0’ 131 106
T30’ 222 132
T60’ 189 144
T90’ 146 116
T120’ 205 129
Insulin (mU/mL)
T0’ 34.6 15.4
T30’ 89.3 34.9
T60’ 110.3 67.8
T90’ 35.4 25.3
T120’ 78.8 31.2
HbA1c 5.6 5.2
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described in the literature. The same mutation was 
detected in the mother and in two maternal aunts 
(one with IGT). 
Therefore, the proposita was started on a 3,5,5’-trii-
odothyroacetic acid (Triac) therapy at the initial dose 
of 1 mg/d. At the same time, nutritional recommenda-
tions and interventions were also initiated for diabetes.
Almost one year after long-term Triac therapy 
(11 years 9 months of age), the girl weighed 30.2 kg 
(-1.83 SDS) and her height was 149.6 cm (-0.11 SDS). 
BMI was 13.49 (-2.78 SDS), according Cacciari et al.8 
The girl had no dysmorphic features. The pubertal 
staging was B2-3-PH2-AH1.
We noted a reduction of thyroid hormone levels: 
fT4 2.47 ng/dL, fT3 5.23 pg/mL, TSH 2.60. We also 
observed an amelioration of glucose and insulin me-
tabolism: HbA1c was 5.2%, basal glycaemia was 104 
mg/dl, and basal insulin was 18.3 μU/mL. However, 
triglycerides were 108 mg/dL, total cholesterol 176 
mg/dL, HDL cholesterol 53 mg/dL, LDL cholesterol 
101 mg/dL. After a new oral glucose tolerance test, 
we hypothesized that glucose metabolism could be 
ameliorated by Triac treatment, possibly by improving 
insulin sensitivity (Table 1). In fact, basal glycaemia 
was 106 mg/dL (116 mg/dL at 120’) and basal insulin 
15.4 μU/mL (31.2 μU/mL at 120’). HOMA index was 
4.03 and Matsuda index 3.50.
dIscussIon
Resistance to thyroid hormone is an uncommon 
disorder characterized by elevated circulating THs 
with nonsuppressed TSH levels, reflecting resist-
ance within the hypothalamic-pituitary-thyroid axis 
but variable refractoriness to hormone action in 
peripheral tissues.9
Clinically, RTH can be divided into two entities: 
generalized (GRTH) and pituitary (PRTH) resist-
ance.3 A molecular mechanism to explain these two 
Figure 1. Electropherogram of gene TRβ in the proposita (a and b) and the mother (c), showing a point mutation at codon 313 
(Met313Val).
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clinical phenotypes has proven elusive and many au-
thors have concluded that they are part of a spectrum 
of the same disorder.10 However, most subjects with 
GRTH are either asymptomatic or have nonspecific 
symptoms and are deemed to be in a compensated 
euthyroid state. In contrast, a subset of affected 
individuals can exhibit some clinical features of hy-
perthyroidism, suggesting greater central or pituitary 
RTH than in peripheral tissues.11
A possible, partial, explanation may be tissue-
dependent TRs expression. In fact, although TRa1 
and TRb1 are expressed ubiquitously, TRa1 is ex-
pressed predominantly in the heart, bone, brain, and 
skeletal muscle,11 whereas TRβ1 is expressed more 
abundantly in liver, kidney, and thyroid.10 However, 
TRβ2 expression is limited to the pituitary gland, 
hypothalamus, retina, and inner ear.10
In the murin pancreas, TRa1 is mainly expressed 
in a-cells.12 On the other hand, T3 rapidly induces 
Akt activation, with specific non-genomic action, 
in pancreatic β-cells via TRβ1. Thus, T3 could be 
considered a survival factor protecting islet β-cells 
from apoptosis.13 Besides this, the predominance of 
an α receptor isoform in skeletal muscle may explain 
retention of sensitivity to TH by this target tissue, 
though some observations also support the notion 
that skeletal muscle is less refractory to TH action 
than the hypothalamic-pituitary axis in RTH.11
Patients with RTH usually present with goiter and 
a euthyroid or mildly hypothyroid metabolic state.14 
However, the clinical presentation of the disease may 
be hypothyroidism, with symptoms such as delayed 
growth, cognitive dysfunction, and hypercholester-
olaemia and, concurrently, signs consistent with 
hyperthyroidism, including tachycardia, weight loss, 
attention deficit-hyperactivity disorder, and advanced 
bone age.15 The hypothyroid-like effects are presum-
ably the consequence of mutant TRβ interference 
with, or inhibition of, normal T3 signalling pathways, 
whereas the signs reflective of hyperthyroidism result 
from the elevated T3 driving the activity of the TRα1 
isoform.15
The secondary occurrence of T2DM with pitui-
tary, adrenal, and/or thyroid diseases is a recurrent 
observation.16 Indeed, IGT and overt diabetes mellitus 
have frequently been associated with acromegaly, 
hypercortisolism, and hyperthyroidism.16 
Several studies evaluating the genomic and non-
genomic effects of TH on insulin secretion have been 
conducted in order to clarify the mechanism(s) behind 
the IGT observed in hyperthyroidism.17 For example, 
in rats treated with high and low doses of T4, fasting 
blood glucose levels were increased, but serum insulin 
levels were similar to those of controls.17 By contrast, 
in rats treated only with high doses of T4, after an oral 
glucose load, blood glucose levels were increased, 
but serum insulin levels were decreased.17 Hence, 
in animals, a deficient pancreatic β-cell response to 
glucose, rather than insulin resistance, seems to be 
responsible for the abnormal glucose tolerance.17
Notwithstanding, in humans, a recent study of 
Mitchell et al showed that RTH subjects exhibited 
insulin resistance as reflected by HOMA-IR.11 In 
fact, in a subgroup of five RTH patients undergoing 
an OGTT, the ISI tended to be significantly lower 
and HOMA significantly higher than controls, clearly 
indicating the presence of an insulin-resistance.11 
One possible explanation for these discrepant 
results between animal models and humans may be 
that besides stimulating muscle fat oxidation and 
mitochondrial energy uncoupling in skeletal muscle, 
TH also promotes myocellular lipogenesis. A further 
possibility is that the liver RTH action might influence 
hepatic insulin sensitivity.11 
A key phenotype associated with T2DM in humans 
is impaired mitochondrial oxidative metabolism in 
skeletal muscle, a pattern potentially contributing to 
increased lipid accumulation and impaired metabolic 
flexibility, in turn, central features of both insulin 
resistance and diabetes.18 In fact, the insulin-resistant 
state with hyperglycaemia may also be due to TH 
effects on mitochondrial content and activity, which 
is important for steroidogenesis as well as insulin 
secretion and action.19,20
However, in thyrotoxicosis, insulin levels are de-
termined by two key factors: increased release of 
biologically inactive insulin precursors and increased 
insulin breakdown. β-cell response to a meal in pa-
tients with Graves’ disease is characterized by a high 
proinsulin output in the hyperglycaemic state.21 The 
ratio of C-peptide to proinsulin is decreased, suggest-
ing a defect in the cleaving process.22 The increase in 
cardiac output in hyperthyroidism leads to increased 
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glomerular filtration rate and therefore increased 
insulin clearance. The combination of increased 
proinsulin secretion and increased insulin clearance 
results in a reduced steady state of circulating insulin 
in hyperthyroidism (Figure 2).
In addition to these secretion and clearance al-
terations, overweight hyperthyroid women lose their 
first-phase response to hyperglycaemia, demonstrating 
lower insulin peaks after intravenous glucose chal-
lenge, similar to what is observed in patients with 
early T2DM.23
Finally, an interesting aspect of our case report 
may be the possible effect, certainly also associated 
with changes related to the lifestyle of our patient, 
of Triac treatment on glucose metabolism. Although 
there is to date no scientific elucidation of the action 
of Triac on the insulinaemic metabolism, it is known 
that Triac has a higher affinity for TRβ1.24 However, 
Triac inhibits leptin secretion and expression in white 
and brown adipocytes, whereas insulin has the op-
posite effect.25 In particular, leptin exerts antidiabetic 
actions that are independent of its regulation of 
body weight and food intake,26 correcting diabetes 
in animal models of type 1 and type 2 diabetes. In 
addition, long-term leptin replacement therapy seems 
to improve glycaemic control as well as insulin sen-
sitivity in patients with severe insulin resistance due 
to lipodystrophy.26
In conclusion, our data seem to show that some 
patients with RTH may develop an impaired glucose 
metabolism. We therefore suggest that glucose me-
tabolism should be investigated in all patients with 
RTH.
references
1. Gurnell M, Rajanayagam o, agostini M, et al, 1999 three 
novel mutations at serine 314 in the thyroid hormone 
beta receptor differentially impair ligand binding in the 
syndrome of resistance to thyroid hormone. Endocrinol-
ogy 140: 5901-5906.
2. Refetoff S, 2005 Resistance to thyroid hormone. In: 
Braverman lE, utiger RE (eds), Werner and Ingbar’s 
the thyroid: a fundamental and clinical text. Philadelphia: 
lippincott, Williams and Wilkins; pp, 1109-1129.
3. Safer JD, langlois MF, Cohen R, et al, 1997 Isoform 
variable action among thyroid hormone receptor mutants 
provides insight into pituitary resistance to thyroid hor-
mone. Mol Endocrinol 11: 16-26.
4. takeda K, Sakurai a, DeGroot lJ, Refetoff S, 1992 Re-
cessive inheritance of thyroid hormone resistance caused 
by complete deletion of the protein-coding region of the 
thyroid hormone receptor-beta gene. J Clin Endocrinol 
Metab 74: 49-55.
5. Refetoff S, Weiss RE, usala SJ, 1993 the syndromes of 
resistance to thyroid hormone. Endocr Rev 14: 348-399.
6. Refetoff S, DeWind lt, DeGroot lJ, 1967 Familial 
syndrome combining deaf-mutism, stuppled epiphyses, 
goiter and abnormally high PBI: possible target organ 
refractoriness to thyroid hormone. J Clin Endocrinol 
Metab 27: 279-294.
7. Kourides Ia, Pekonen F, Weintraub BD, 1980 absence 
of thyroid-binding immunoglobulins in patients with 
thyrotropin-mediated hyperthyroidism. J Clin Endocrinol 
Metab 51: 272-274.
8. Cacciari E, Milani S, Balsamo a, et al, 2006 Italian 
cross-sectional growth charts for height, weight and BMI 
(2 to 20 yr). J Endocrinol Invest 29: 581-593.
9. hamon P, Bovier-lapierre M, Robert M, Peynaud D, 
Pugeat M, orgiazzi J, 1988 hyperthyroidism due to 
selective pituitary resistance to thyroid hormones in a 
15-month-old boy: efficacy of D-thyroxine therapy. J 
Clin Endocrinol Metab 67: 1089-1093.
10. Beck-Peccoz P, Chatterjee VK, 1994 the variable clini-
cal phenotype in thyroid hormone resistance syndrome. 
thyroid 4: 225-232. 
Figure 2. The effects of excess thyroid hormone on various or-
gan systems resulting in altered glucose metabolism, potential-
ly leading to diabetic ketoacidosis and thyroid storm. Thyroid 
hormone increases hepatic glucose output, decreases periph-
eral glucose disposal, increases inactive insulin secretion by the 
pancreas, and increases insulin clearance by the kidney. TSH 
indicates thyrotropin.
Diabetes and thyroid hormone resistance  567
11. Mitchell CS, Savage DB, Dufour S, et al, 2010 Resist-
ance to thyroid hormone is associated with raised energy 
expenditure, muscle mitochondrial uncoupling, and 
hyperphagia. J Clin Invest 120: 1345-1354.
12. Zinke a, Schmoll D, Zachmann M, et al, 2003 Expression 
of thyroid hormone receptor isoform alpha1 in pancre-
atic islets. Exp Clin Endocrinol Diabetes 111: 198-202.
13. Verga Falzacappa C, Petrucci E, Patriarca V, et al, 2007 
thyroid hormone receptor tRbeta1 mediates akt acti-
vation by t3 in pancreatic beta cells. J Mol Endocrinol 
38: 221-233. 
14. Kopp P, Kitajima K, Jameson Jl, 1996 Syndrome of 
resistance to thyroid hormone: insights into thyroid 
hormone action. Proc Soc Exp Biol Med 211: 49-61.
15. Zhang XY, Kaneshige M, Kamiya Y, Kaneshige K, 
McPhie P, Cheng SY, 2002 Differential expression of 
thyroid hormone receptor isoforms dictates the dominant 
negative activity of mutant Beta receptor. Mol Endocrinol 
16: 2077-2092. 
16. Resmini E, Minuto F, Colao a, Ferone D, 2009 Second-
ary diabetes associated with principal endocrinopathies: 
the impact of new treatment modalities. acta Diabetol 
46: 85-95.
17. Fukuchi M, Shimabukuro M, Shimajiri Y, et al, 2002 
Evidence for a deficient pancreatic beta-cell response in 
a rat model of hyperthyroidism. life Sci 71: 1059-1070.
18. Crunkhorn S, Patti ME, 2008 links between thyroid 
hormone action, oxidative metabolism, and diabetes 
risk? thyroid 18: 227-237.
19. Stark R, Roden M, 2007 ESCI award 2006. Mitochon-
drial function and endocrine diseases. Eur J Clin Invest 
37: 236-248.
20. abdullah N, al-Khalidi o, Brown KJ, Reid J, Cheetham 
tD, 2008 Prolonged honeymoon phase in an adolescent 
with diabetes and thyrotoxicosis provides support for 
the accelerator hypothesis. Pediatr Diabetes 9: 417-419.
21. Bech K, Damsbo P, Eldrup E, et al, 1996 beta-cell func-
tion and glucose and lipid oxidation in Graves’ disease. 
Clin Endocrinol (oxf) 44: 59-66.
22. Beer SF, Parr Jh, temple RC, hales CN, 1989 the effect 
of thyroid disease on proinsulin and C-peptide levels. 
Clin Endocrinol (oxf) 30: 379-383.
23. ohguni S, Notsu K, Kato Y, 1995 Correlation of plasma 
free thyroxine levels with insulin sensitivity and metabolic 
clearance rate of insulin in patients with hyperthyroid 
Graves’ disease. Intern Med 34: 339-341.
24. takeda t, Suzuki S, liu Rt, DeGroot lJ, 1995 trii-
odothyroacetic acid has unique potential for therapy of 
resistance to thyroid hormone. J Clin Endocrinol Metab 
80: 2033-2040.
25. Medina-Gomez G, Calvo RM, obregón MJ, 2004 t3 and 
triac inhibit leptin secretion and expression in brown and 
white rat adipocytes. Biochim Biophys acta 1682: 38-47.
26. Coppari R, Bjørbæk C, 2012 leptin revisited: its mecha-
nism of action and potential for treating diabetes. Nat 
Rev Drug Discov 11: 692-708.
